Teva acquires Théramex

NewsGuard 100/100 Score
Jan 5 2011

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed the acquisition of Théramex, Merck KGaA's European-based women's health business.

Théramex brings to Teva a broad portfolio of women's health and gynecology products sold in over 50 countries, primarily France and Italy. Théramex's pipeline includes NOMAC/E2, a new oral contraceptive based on natural estrogens, which has successfully completed phase III studies and was submitted for approval in Europe.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in:

Tags: , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Common HIV drugs linked to reduced Alzheimer's disease risk
Study examines how pregnancy shapes perception and identity
From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech
St. Jude researchers unveil mechanisms to block PXR and enhance drug potency
Research quantifies impact of childhood obesity on long-term health and life expectancy
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Sensing a Healthier Future with Sustainable Nanomaterials and Biosensors

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Georgetown study raises concerns over aspirin's role in breast cancer treatment